Compugen Ltd CGEN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/18/24 EDT
1.88UNCH (UNCH)
Volume
308,257
52 week range
0.53 - 3.03
Loading...
  • Open1.88
  • Day High1.96
  • Day Low1.83
  • Prev Close1.88
  • 52 Week High3.03
  • 52 Week High Date03/08/24
  • 52 Week Low0.53
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap168.317M
  • Shares Out89.53M
  • 10 Day Average Volume0.35M
  • Dividend-
  • Dividend Yield-
  • Beta2.73
  • YTD % Change-5.05

KEY STATS

  • Open1.88
  • Day High1.96
  • Day Low1.83
  • Prev Close1.88
  • 52 Week High3.03
  • 52 Week High Date03/08/24
  • 52 Week Low0.53
  • 52 Week Low Date11/13/23
  • Market Cap168.317M
  • Shares Out89.53M
  • 10 Day Average Volume0.35M
  • Dividend-
  • Dividend Yield-
  • Beta2.73
  • YTD % Change-5.05

RATIOS/PROFITABILITY

  • EPS (TTM)-0.22
  • P/E (TTM)-8.71
  • Fwd P/E (NTM)45.85
  • EBITDA (TTM)-12.992M
  • ROE (TTM)-26.19%
  • Revenue (TTM)33.459M
  • Gross Margin (TTM)94.01%
  • Net Margin (TTM)-56.05%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/13/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Compugen Ltd

 

Profile

MORE
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs...
Paul Sekhri
Non-Executive Independent Chairman of the Board
Anat Cohen-Dayag Ph.D.
President, Chief Executive Officer, Director
Ari Krashin CPA
Chief Financial Officer, Chief Operating Officer
Eran Ophir
Vice President - Research, Drug Discovery
Address
Azrieli Center, 26 Harokmim St. Bldg D
Holon
5885849
Israel